| Ticker | APLS |
|---|---|
| ISIN | US03753U1060 |
| Sector | Atención sanitaria |
| Industria | Biotechnology |
| Mercado | NASDAQ |
| Capitalización | $5.234.638.500 |
| Beta | -0,2 |
| Sitio web | https://www.apellis.com |
| CEO | Cedric Francois |
| Fecha de IPO | 09/11/2017 |
| País | US |
| Dirección | 100 Fifth Avenue, Waltham, MA, 02451 |
| Volumen | 2.553.741 |
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops...
El precio actual de Apellis Pharmaceuticals, Inc. (APLS) es de 40,95, con una variación del -0,10%.
Apellis Pharmaceuticals, Inc. opera en el sector Healthcare, industria Biotechnology.
Compara brokers con acceso a las principales bolsas internacionales, con bajas comisiones, custodia y herramientas de análisis para invertir en acciones.
Compara brokers para acciones